Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | 10% owner | May 09, 2023 | May 11, 2023 |
| AMGEN INCAMGN · Entity 2832 | EVP, Research & Development | July 16, 2018 | July 17, 2018 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | 10% owner | February 12, 2024 | February 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date May 09, 2023 · Filed May 11, 2023
Jointly reported with Westlake BioPartners Fund II, L.P., Westlake BioPartners GP II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,790,729 |
Last balance in matching sequence
After 2023-05-09 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2023-05-09 · Conversion · Acquired 8,540,729 · Balance 8,540,729 F1: Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration. F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. F3: This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose. Row 2 · 2023-05-09 · Purchase · Acquired 1,250,000 · Balance 9,790,729 F4: Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO"). F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. F3: This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose. |
| Series A Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-09 · Conversion · Disposed 4,056,795 · Balance 0 F5: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F6: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. F3: This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-09 · Conversion · Disposed 2,445,786 · Balance 0 F5: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F6: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. F3: This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose. |
| Series C Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-09 · Conversion · Disposed 2,038,148 · Balance 0 F5: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock. F6: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO. F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any. F3: This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Common Stock received upon conversion of shares of the reported series of preferred stock on a one-for-one basis without payment of further consideration.
F2: Shares held directly by Westlake BioPartners Fund II, L.P., or Westlake Fund II. Westlake BioPartners GP II, LLC, or Westlake GP II, is the general partner of Westlake Fund II. Westlake GP II may be deemed to have sole voting and dispositive power with regard to the shares held directly by Westlake Fund II. Beth C. Seidenberg and Sean E. Harper are the Managing Directors of Westlake GP II and share voting and dispositive power over the shares held by Westlake Fund II, each of whom disclaims beneficial ownership of the shares held by Westlake Fund II except to the extent of such person's pecuniary interest therein, if any.
F3: This report on Form 4 is jointly filed by Westlake Fund II, Westlake GP II and Sean E. Harper. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of such person's or entity's pecuniary interest therein, if any. Westlake Fund II has designated a representative, Beth C. Seidenberg, a Managing Director of Westlake GP II, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purposes of Section 16 of the Exchange Act, or for any other purpose.
F4: Represents shares of Common Stock purchased in the Issuer's initial public offering of Common Stock (the "IPO").
F5: Each share of preferred stock is convertible into one share of Common Stock and has no expiration date. Immediately prior to the completion of the IPO, all shares of preferred stock automatically converted into shares of Common Stock.
F6: Each share of Class A Common Stock was reclassified into one share of Common Stock immediately prior to the completion of the IPO.
AMGEN INC
Report date July 16, 2018 · Filed July 17, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,082 |
Reported balance
After 2018-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-07-16 · Sale · Disposed 1,525 · Balance 56,082 F1: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1. F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,340 RSUs which vest in one installment on 1/30/2019; 3,000 RSUs which vest in installments of 1,477 5/3/2019 and 1,523 on 5/3/2020; 4,551 RSUs which vest in installments of 1,501 on 5/1/2019, 1,502 on 5/1/2029 and 1,548 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3: These shares include 495 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was made pursuant to a previously adopted plan complying with Rule 10b5-1.
F2: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,340 RSUs which vest in one installment on 1/30/2019; 3,000 RSUs which vest in installments of 1,477 5/3/2019 and 1,523 on 5/3/2020; 4,551 RSUs which vest in installments of 1,501 on 5/1/2019, 1,502 on 5/1/2029 and 1,548 on 5/1/2021; and 4,508 RSUs which vest in installments of 1,487 on 4/27/2020, 1,488 on 4/27/2021 and 1,533 on 4/27/2022. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3: These shares include 495 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
Kyverna Therapeutics, Inc.
Report date February 12, 2024 · Filed February 14, 2024
Jointly reported with Westlake BioPartners Fund I, L.P., Westlake BioPartners GP I, LLC, Westlake BioPartners Opportunity Fund I, L.P., Westlake BioPartners Opportunity GP I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 3,787,940 |
Reported balance
After 2024-02-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-02-12 · Conversion · Acquired 3,787,940 · Balance 3,787,940 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 735,984 |
Reported balance
After 2024-02-12 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-02-12 · Conversion · Acquired 735,984 · Balance 735,984 F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration. F3: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. |
| Series A-1 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2024-02-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-12 · Conversion · Disposed 4,401,771 · Balance 0 F4: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. |
| Series A-2 Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2024-02-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-12 · Conversion · Disposed 8,830,901 · Balance 0 F4: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2024-02-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-12 · Conversion · Disposed 4,006,624 · Balance 0 F4: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any. |
| Series B Redeemable Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2024-02-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-12 · Conversion · Disposed 3,349,538 · Balance 0 F4: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering. F3: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2: Shares held directly by Westlake BioPartners Fund I, L.P. ("Westlake I"). The general partner of Westlake I is Westlake BioPartners GP I, LLC ("Westlake GP I"). The voting and dispositive control over Westlake GP I is shared by the managing directors of Westlake GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake I except to the extent of such person's pecuniary interest therein, if any.
F3: Shares held directly by Westlake BioPartners Opportunity Fund I, L.P. ("Westlake Opportunity"). The general partner of Westlake Opportunity is Westlake BioPartners Opportunity GP I, LLC ("Westlake Opportunity GP I"). The voting and dispositive control over Westlake Opportunity GP I is shared by the managing directors of Westlake Opportunity GP I, Beth Seidenberg and Sean Harper, none of whom has veto power, and each of whom disclaims beneficial ownership of the shares held by Westlake Opportunity except to the extent of such person's pecuniary interest therein, if any.
F4: The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 28, 2015 Filed Jan 30, 2015 21:56 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 928 | $158.89 | $147,449.92 |
DisclosureSEC source: 0001127602-15-003486 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,680 Read SEC document |
| December 31, 2014 Filed Jan 5, 2015 21:22 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 13,046 | $160.63 | $2,095,578.98 |
DisclosureSEC source: 0001127602-15-000660 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,608 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 664 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| August 05, 2014 Filed Aug 7, 2014 20:22 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 14,000 | $127.29 | $1,782,125.80 |
DisclosureSEC source: 0001127602-14-024954 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,503 F1 · price: The price reported is an average price. The prices ranged from $127.21 to $127.46 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 12/31/2014; 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 513 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 56 | $111.41 | $6,238.96 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 4 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,407 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 25,000 RSUs which fully vest on 12/31/2014; 2,040 RSUs which vest in one installment of 2,040 on 4/25/2015; 5,799 RSUs which vest in two installments of 2,856 and 2,943 on 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 417 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 27, 2014 Filed Apr 29, 2014 21:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,490 | $111.41 | $166,000.90 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 3 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,463 Read SEC document |
| April 26, 2014 Filed Apr 29, 2014 21:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 601 | $111.41 | $66,957.41 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,953 Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:42 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,034 | $113.72 | $117,586.48 |
DisclosureSEC source: 0001127602-14-015507 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,554 Read SEC document |
| March 14, 2014 Filed Mar 18, 2014 20:26 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 7,683 | $123.96 | $952,384.68 |
DisclosureSEC source: 0001127602-14-012021 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,588 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 523 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 05, 2014 Filed Mar 7, 2014 22:29 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 14,724 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-010751 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,163 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 31, 2014 Filed Feb 4, 2014 22:43 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 5,044 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-14-004380 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,439 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017; and 5,044 RSUs which vest in three installments of 1,664, 1,665 and 1,715 on 1/31/2016, 1/31/2017 and 1/31/2018, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 415 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2013 Filed May 6, 2013 21:27 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-13-015815 · form4.xml · derivative · entry 3 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,000 shares Expires 2016-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 02, 2013 Filed May 6, 2013 21:27 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 8,000 | $106.32 | $850,589.60 |
DisclosureSEC source: 0001127602-13-015815 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,180 F1 · price: The price reported is an average price. The prices ranged from $106.30 to $106.35 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| May 02, 2013 Filed May 6, 2013 21:27 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 8,000 | $50.44 | $403,520.00 |
DisclosureSEC source: 0001127602-13-015815 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,180 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2013 Filed Apr 30, 2013 21:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 588 | $108.38 | $63,727.44 |
DisclosureSEC source: 0001127602-13-014771 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,180 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,150 RSUs which fully vest on 4/26/2014; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:18 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 601 | $108.66 | $65,304.66 |
DisclosureSEC source: 0001127602-13-014771 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,768 Read SEC document |
| April 25, 2013 Filed Apr 29, 2013 22:04 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,034 | $104.93 | $108,497.62 |
DisclosureSEC source: 0001127602-13-014707 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,369 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 4,020 RSUs which vest in one installment of 1,980 on 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 15, 2013 Filed Mar 19, 2013 23:43 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 6,918 | $92.18 | $637,701.24 |
DisclosureSEC source: 0001127602-13-011474 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,403 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 200 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 23:35 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 13,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-010169 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,238 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F2 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| January 28, 2013 Filed Jan 31, 2013 01:20 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 7,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-13-003266 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,981 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 1/28/2015, 1/28/2016 and 1/28/2017, respectively. F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively; and 7,477 RSUs which vest in two equal installments of 2,467 each on 1/28/2015 and 1/28/2016 and one installment of 2,543 on 1/28/2017. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 117 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 14,400 | $0.00 Strike: $69.78 | $0.00 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · derivative · entry 9 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,400 shares Expires 2014-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 16,109 | $0.00 Strike: $71.88 | $0.00 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · derivative · entry 8 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,109 shares Expires 2013-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · derivative · entry 7 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 8,000 shares Expires 2020-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionIso (Right to Buy) · Derivative | 1,391 | $0.00 Strike: $71.88 | $0.00 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · derivative · entry 6 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,391 shares Expires 2013-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | SaleCommon Stock | 39,900 | $82.33 | $3,285,086.70 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · nonDerivative · entry 5 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,432 F1 · price: The price reported is an average price. The prices ranged from $82.28 to $82.48 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer. F2 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. F3 · balance_after: These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 14,400 | $69.78 | $1,004,832.00 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · nonDerivative · entry 4 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 16,109 | $71.88 | $1,157,914.92 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · nonDerivative · entry 3 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 8,000 | $58.43 | $467,440.00 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 27, 2012 Filed Jul 31, 2012 23:35 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 1,391 | $71.88 | $99,985.08 |
DisclosureSEC source: 0001127602-12-023278 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2012 Filed May 4, 2012 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $50.44 | $0.00 |
DisclosureSEC source: 0001127602-12-015861 · form4.xml · derivative · entry 6 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2016-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2012 Filed May 4, 2012 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionNqso (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $42.13 | $0.00 |
DisclosureSEC source: 0001127602-12-015861 · form4.xml · derivative · entry 5 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2015-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2012 Filed May 4, 2012 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 6,758 | $71.17 | $480,966.86 |
DisclosureSEC source: 0001127602-12-015861 · form4.xml · nonDerivative · entry 4 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,387 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| May 03, 2012 Filed May 4, 2012 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 4,695 | $71.17 | $334,143.15 |
DisclosureSEC source: 0001127602-12-015861 · form4.xml · nonDerivative · entry 3 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,145 Read SEC document |
| May 03, 2012 Filed May 4, 2012 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 8,000 | $50.44 | $403,520.00 |
DisclosureSEC source: 0001127602-12-015861 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2012 Filed May 4, 2012 01:13 UTC | AMGEN INC AMGN · Entity 2832 | Exercise / conversionCommon Stock | 6,000 | $42.13 | $252,780.00 |
DisclosureSEC source: 0001127602-12-015861 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 29, 2012 Filed May 2, 2012 00:51 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 2,545 | $71.64 | $182,323.80 |
DisclosureSEC source: 0001127602-12-015251 · form4.xml · nonDerivative · entry 3 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,840 F2 · balance_after: These shares include the following RSUs granted under the Company's equity plans: 1,125 RSUs which fully vest on 4/28/2013; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| April 28, 2012 Filed May 2, 2012 00:51 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 526 | $71.64 | $37,682.64 |
DisclosureSEC source: 0001127602-12-015251 · form4.xml · nonDerivative · entry 2 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,385 Read SEC document |
| April 27, 2012 Filed May 2, 2012 00:51 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 8,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-015251 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,911 F1 · shares: The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Read SEC document |
| April 26, 2012 Filed Apr 30, 2012 21:12 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 514 | $70.19 | $36,077.66 |
DisclosureSEC source: 0001127602-12-014950 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,257 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,450 RSUs which fully vest on 4/29/2012; 2,250 RSUs which vest in two equal annual installments of 1,125 each commencing 4/28/2012; 2,300 RSUs which vest in two equal annual installments of 1,150 each commencing on 4/26/2013; 25,000 RSUs which fully vest on 12/31/2014; and 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
| March 16, 2012 Filed Mar 20, 2012 21:50 UTC | AMGEN INC AMGN · Entity 2832 | Tax withholdingCommon Stock | 1,519 | $68.26 | $103,686.94 |
DisclosureSEC source: 0001127602-12-011448 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,771 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,450 RSUs which fully vest on 4/29/2012; 2,250 RSUs which vest in two equal annual installments of 1,125 each commencing 4/28/2012; 3,450 RSUs which vest in three equal annual installments of 1,150 each commencing 4/26/2012; 25,000 RSUs which fully vest on 12/31/2014; and 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis Read SEC document |
| March 14, 2012 Filed Mar 15, 2012 23:54 UTC | AMGEN INC AMGN · Entity 2832 | GrantCommon Stock | 4,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-12-010815 · form4.xml · nonDerivative · entry 1 Harper Sean E · CIK 0001541946 · EVP, Research & Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,290 F1 · balance_after: These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 5,450 RSUs which fully vest on 4/29/2012; 2,250 RSUs which vest in two equal annual installments of 1,125 each commencing 4/28/2012; 3,450 RSUs which vest in three equal annual installments of 1,150 each commencing 4/26/2012; 25,000 RSUs which fully vest on 12/31/2014; and 6,000 RSUs which vest in two equal installments of 1,980 each on 4/25/2013 and 4/25/2014 and one installment of 2,040 on 4/25/2015. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.